SPOTLIGHT -
In August 2022, the FDA approved betibeglogene autotemcel for adult and pediatric patients with β-thalassemia who need regular red blood cell infusions.
FDA Approves Beti-Cel in Transfusion-Dependent β-Thalassemia in Pediatrics and Adults
Pediatric and adult patients who have β -thalassemia and need regular red blood cell infusions may now receive betibeglogene autotemcel, which has been approved by the FDA.
Alexis A. Thompson, MD, MPH, Considers Future Assessments of Beti-Cel in β-Thalassemia
Alexis A. Thompson, MD, MPH, reviewed the unmet needs of patients with β-thalassemia who will receive betibeglogene autotemcel.
Alexis A. Thompson, MD, MPH, Assesses the Need for Beti-Cel in β-Thalassemia
Alexis A. Thompson, MD, MPH, reviewed unmet needs for patients with β-thalassemia who may now receive betibeglogene autotemcel.